Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells..dysfunction of the autophagy–lysosome system, has been described in post-mortem Parkinson’s disease brain (Alvarez-Erviti et al., 2010; Dehay et al., 2013). In addition cell biology studies have demonstrated that inhibition of the autophagy–lysosome system, and in particular chaperone-mediated autophagy, is associated with elevation of alpha-synuclein protein levels
AiM-PD study:
Between January 2017 and April 2018 a phase 2 clinical trial ‘Ambroxol in Disease Modification in Parkinson Disease’ (the AiM-PD study) was conducted by. The results of this clinical study have now been published in JAMA Neurology.
Study result – Ambroxol for PD phase 2 >>(Jama)
Dosage: Ambroxol (1.26g/day)